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Background: Calcium and magnesium (Ca/Mg) infusions have been suggested as an effective intervention for
preventing oxaliplatin-induced neurotoxicity, but the effects of Ca/Mg infusions on oxaliplatin pharmacokinetics,
motor nerve hyperexcitability and acute neurotoxicity symptoms are unclear.
Methods: In this double blind crossover study, colorectal cancer patients undergoing oxaliplatin-based chemotherapy
were randomised to receive Ca/Mg (1g Ca Gluconate plus 1g MgSO4) on cycle 1 and placebo (vehicle alone) on cycle
2, or to receive the same treatments in the opposite sequence. Study endpoints included plasma pharmacokinetics of
intact oxaliplatin and free platinum; electromyography (EMG) detection of abnormal spontaneous high-frequency
motor unit action potential discharges; and patient-reported acute neurotoxicity symptoms and their preferred study
treatment for reducing these symptoms.
Results: Nineteen of 20 enrolled patients completed the study. Plasma pharmacokinetics of intact oxaliplatin and free
platinum were similar when oxaliplatin was given with Ca/Mg or placebo (ratio of geometric means of AUC0-t with
Ca/Mg or placebo: intact oxaliplatin, 0.95 (90% CI, 0.90 – 1.01); free platinum, 0.99 (90% CI, 0.94 – 1.05)). EMG motor
nerve hyperexcitability scores were similar with Ca/Mg and placebo (mean difference in EMG score between Ca/Mg
and placebo: -0.3 (95% CI, -2.2 – 1.6)). Patient-reported acute neurotoxicity symptoms were similar in frequency with
Ca/Mg and placebo. For reducing neurotoxic symptoms, fewer patients preferred Ca/Mg than placebo or neither
treatment (26% versus 74%; P<0.01).
Conclusions: Ca/Mg infusions do not alter the clinical pharmacokinetics of oxaliplatin and do not seem to reduce its
acute neurotoxicity.
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Oxaliplatin-based chemotherapy has become an important
treatment for gastrointestinal cancers, including colo-
rectal, esophagogastric and pancreatic cancers [1-8]. In
particular, it is a standard therapy for colorectal cancer
in both the adjuvant and palliative settings [1,4-7]. Per-
ipheral neurotoxicity is a major dose-limiting toxicity
of oxaliplatin, which may compromise the delivery and
full therapeutic potential of this drug to achieve tumour
control or cure. Acute neurotoxicity occurs in a high
proportion of patients shortly after oxaliplatin administra-
tion, but may resolve within a few hours or days, and is
characterised by cold-related paresthesia, dysesthesia or
allodynia, jaw stiffness, and muscle cramps [9]. These
acute symptoms may reflect the induction of a state of
acute peripheral nerve hyperexcitability detectable on
electromyography (EMG) and other neurophysiological
studies after oxaliplatin treatment [10-12]. Chronic per-
ipheral sensory neurotoxicity from oxaliplatin can also be
troublesome and is characterised by glove-and-stocking
paresthesia and dysesthesia, and loss of peripheral deep
tendon reflexes, vibration sensation and proprioception
[9]. Its recovery after discontinuation of oxaliplatin may
be slow, improving gradually over many months or even
years, and is incomplete in some patients.
Calcium and magnesium (Ca/Mg) infusions were
adopted by many oncologists in an attempt to reduce
oxaliplatin-induced neurotoxicity based on the results
of a retrospective analysis by Gamelin et al. [13] and
subsequent reports [14]. However, there had been no
consensus about the efficacy of Ca/Mg infusions for
preventing oxaliplatin-induced neurotoxicity, and con-
siderable variation existed in clinical practice with the
use of this otherwise simple intervention. The mechanisms
of the neuroprotective action of Ca/Mg infusions were
also unknown. Several mechanisms have been postulated
involving sodium or other ion channels [15], but these are
unsubstantiated. We hypothesised that Ca/Mg infusions
could reduce oxaliplatin neurotoxicity by altering the
pharmacokinetics of oxaliplatin or by suppressing per-
ipheral nerve hyperexcitability induced by oxaliplatin,
possibly via an ion channel mechanism. Recently, we
found that the conversion of oxaliplatin to its major
degradation product, Pt(DACH)Cl2, is accelerated in the
presence of calcium or magnesium ions in physiological
chloride solutions in vitro, suggesting the potential for
a pharmacokinetic interaction to exist between oxali-
platin and Ca/Mg infusions in cancer patients [16]. Pre-
viously, we had also developed techniques for detecting
and measuring oxaliplatin-induced peripheral nerve
hyperexcitability in cancer patients based on EMG [10],
and for quantitating intact oxaliplatin and free pla-
tinum in human plasma samples [17], for application
in this study.In the current cross-over study, we aimed to determine
the effect of Ca/Mg infusions on the pharmacokinetics
of intact oxaliplatin and free platinum in colorectal can-
cer patients undergoing oxaliplatin-based chemotherapy.
Pharmacokinetic studies were carried out on cycles one
and two of oxaliplatin treatment using fully validated
sample processing and bioanalytical techniques, based
on high-performance liquid chromatography (HPLC)
and inductively coupled plasma mass spectrometry (ICP-
MS). The effects of Ca/Mg infusions on acute oxaliplatin-
induced motor nerve hyperexcitability were previously
unknown, but objectively evaluated in the current study
using EMG techniques. Study patients reported their
acute neurotoxicity symptoms and which study treatment
they preferred for reducing these symptoms. To reduce
bias, patients and researchers, including the neurophy-
siologist and bioanalyst, were blinded to study treat-
ment details, and the study used a prospective design,
placebo control and random assignment of the sequence
of study treatments.Methods
Patients
Eligible subjects were adult patients with colorectal
cancer who were to receive standard chemotherapy with
an oxaliplatin-based regimen (XELOX or mFOLFOX6)
and who had given written informed consent. Subjects
with pre-existing peripheral neuropathy, hypercalcemia,
hypermagnesemia or medical contraindications to elec-
tromyography (EMG) or repeated pharmacokinetic blood
sampling were ineligible. The study was approved by the
Northern Y Regional Ethics Committee (Approval number
NTY/11/01/005).Design
This was a prospective, randomised, double-blind, placebo-
controlled, cross-over study. Patients were randomly
allocated to receive either intravenous Ca/Mg (1g calcium
gluconate plus 1g magnesium sulphate in 100 ml 5%
dextrose) or placebo (100 ml 5% dextrose) over 15
minutes immediately before and after a two hour oxali-
platin infusion on cycle 1 then crossed over to the
other study treatment on cycle 2. Randomisation was
carried out by sealed envelope using 1:1 allocation,
stratification for oxaliplatin dose (130 mg/m2 versus 85
mg/m2) and a block size of four. Double-blinding was
achieved by neither the patients nor any of the research
staff knowing the treatment assignment, except an
independent oncology nurse who carried out the ran-
domisation, made up the study infusion and recorded
the treatment assignment. The active and placebo
study treatments were made in identical 5% dextrose
100 ml infusion bags. Patients received standard
Table 1 Baseline clinical characteristics (n=20)
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to the standard protocols of our institution.
Endpoints
The primary endpoint was plasma pharmacokinetic
parameters of intact oxaliplatin, including area under
the concentration versus time curve from time zero
to the last sample (AUC0-t), mean residence time (MRT),
clearance (Cl), peak plasma concentration (Cmax), and
volume of distribution at steady state (Vss). The secondary
endpoints included free platinum pharmacokinetic pa-
rameters, EMG detected abnormal spontaneous high-
frequency motor unit action potentials, patient-reported
neurotoxicity symptoms and study treatment preference
for reducing neurotoxicity symptoms at the end of cycle 2.
Pharmacokinetic procedures and analysis
On the day of treatment, blood samples were collected
at each of the following time points: pre-infusion; at 20,
40, 60 and 90 minutes after the start of the oxaliplatin
infusion; at the end of the infusion and 5, 10, 20, 30, 60,
120 and 180 minutes thereafter. As oxaliplatin is highly
unstable in blood and plasma, blood samples were
immediately processed to prepare methanol-deproteinised
plasma, snap frozen in liquid nitrogen then stored at −80°C
until analysis, under which conditions oxaliplatin remains
stable [17]. Plasma concentrations of intact oxaliplatin
and free platinum were determined by validated HPLC
and ICP-MS method [17]. Calibration curve linearity
(R2 > 0.99), accuracy (> 86%) and precision (< 13%), both
within and between runs, fulfilled the requirements for
validated bioanalytical assays [18]. Pharmacokinetic
parameters were calculated using non-compartmental
methods and PKSolver [19]. Pharmacokinetic analyses












Spinal injury 1 5
1ECOG, Eastern Cooperative Oncology Group.
2XELOX, 2-hour infusion of oxaliplatin (130 mg/m2) followed by oral
capecitabine (1250 mg/m2) twice daily day 1 to day 14 every 3 weeks.
3FOLFOX6, 2-hour infusion of oxaliplatin (85 mg/m2) together with 2-hour
infusion of leucovorin (400 mg/m2) followed by a fluorouracil bolus
(400 mg/m2) and 46-hour infusion (2,400 mg/m2) every 2 weeks.Neurophysiological assessment
An EMG was performed on day 2 of each study cycle to
assess motor nerve hyperexcitability by a neurophysiologist
who was blinded to the study treatment assignment.
Standard EMG procedures were used and limb tem-
perature was monitored and maintained above 32°C.
EMG was performed in the first dorsal interosseous, ex-
tensor digitorum communis, tibialis anterior and gastro-
cnemius muscles. Motor unit activity was scored as in our
previous study [10]:
0 No abnormal motor unit activity
1 increased insertional activity
2 spontaneous high frequency motor unit activity with
muscle clinically at rest, with bursts lasting for
duration of less than 2 seconds3 spontaneous high frequency motor unit activity with
muscle clinically at rest, with bursts lasting for
duration of 2 to 5 seconds
4 spontaneous high frequency motor unit activity with
muscle clinically at rest, with bursts lasting for
duration of more than 5 seconds.
The final EMG score was calculated as the sum of
scores from the four muscles tested on each cycle for
each patient (minimum value, 0; maximum value, 16).
Patient-reported neurotoxicity symptom evaluation
Patients completed a questionnaire after treatment cycles
1 and 2 to document the presence or absence of acute
neurotoxicity symptoms (cold-induced paresthesia, jaw or
throat tightness, pain at infusion site, paresthesia unrelated
to cold, muscle cramps, change in vision, shortness of
breath or other neurotoxicity symptoms). At the end of
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study treatments given for reducing neurotoxicity they
preferred (cycle 1, cycle 2 or no preference).
Statistical analysis
The statistical analysis of the primary endpoint was car-
ried out in accordance with recommendations for the
analysis of drug interaction studies by the US Food and
Drug Administration [20]. As recommended, geometric
mean and 90% confidence intervals (CI) of each pharma-
cokinetic parameter ratio for evaluable patients were
calculated. If the 90% CIs for the geometric mean ratio fell
within a no-effect boundary of between 80% and 125%,
then it was to be concluded that there was no significant
effect of Ca/Mg infusions on the pharmacokinetics of
oxaliplatin. No additional dose-normalization was required
as each pharmacokinetic parameter for each patient
was expressed as ratio of that with Ca/Mg infusions versus
placebo. Descriptive statistics were used to analyse the
EMG data and patient-reported neurotoxicity outcomes.
The statistical significance of differences in means and
proportions between the placebo and Ca/Mg infusion
groups were analysed by a paired t-test and Chi-square
test, respectively. P values less than 0.05 were regarded as
indicating statistical significance.
The study sample size was calculated based on the 90%
CI for the geometric mean ratio of oxaliplatin pharma-
cokinetic parameters when oxaliplatin is given with and
without Ca/Mg infusions, and coefficient of variationsFigure 1 CONSORT diagram.of oxaliplatin pharmacokinetic parameters of 25% or less.
On this basis, a sample size of 12 evaluable patients was
needed to define 90% CI for pharmacokinetic parameter
ratio of ± 0.12 and for detecting a change in oxaliplatin
pharmacokinetics of 25% or more with statistical signifi-
cance. To allow for dropouts and discontinuations, a total
of 20 patients were planned for enrolment.
Results
Patients and treatment
A total of 20 patients were enrolled between June 2011
and July 2012 who were to receive either XELOX (16
patients) or modified FOLFOX6 (4 patients) for colorectal
adenocarcinoma. None of the patients had prior chemo-
therapy or abnormal serum calcium and magnesium levels.
Baseline patient characteristics (Table 1) were well
balanced between those randomly allocated to receive
Ca/Mg infusions on the first cycle of chemotherapy
then placebo infusion on the second treatment cycle,
and those allocated to receive the same study treatments
but in the opposite sequence. All patients completed
the study except one patient who developed severe
chemotherapy related enterocolitis and stopped chemo-
therapy after cycle one; therefore, this patient was not
evaluable (Figure 1). A total of 38 treatment cycles was
available for analysis (19 for placebo and 19 for Ca/Mg).
All 19 patients completing the study received the same
dose of oxaliplatin on both treatment cycles except one
patient who had a 10% dose reduction for cycle 2 due
Figure 2 Plasma concentration versus time curves. For (A) intact
oxaliplatin and (B) free platinum in colorectal cancer patients (n=19)
given oxaliplatin with placebo (blue circle and line) or Ca/Mg
infusions (gold diamond and line). Data points represent the
geometric mean and bars the standard deviation. The horizontal line
at the bottom of the figure represents the duration and sequence of
study treatments.
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adverse effects attributable to the placebo or Ca/Mg
infusions.
Pharmacokinetics
Plasma concentrations versus time profiles of intact
oxaliplatin (Figure 2A) and free platinum (Figure 2B)
were similar when oxaliplatin was given with and with-
out Ca/Mg infusions. Plasma concentrations of intact
oxaliplatin and free platinum increased during the first
hour of the oxaliplatin infusion, plateaued during the se-
cond hour, and then decreased rapidly after the end of the
oxaliplatin infusion. The plasma concentration values for
free platinum appeared to be similar or slightly higher
than those for intact oxaliplatin at each time point.
Pharmacokinetic parameters of both intact oxaliplatin
and free platinum were similar when oxaliplatin was given
with Ca/Mg or placebo (Table 2). Ratios of geometric
mean values of AUC0-t, Cmax, Cl, Vss and MRT for Ca/Mg
versus placebo ranged from 0.95 to 1.06 and their respec-
tive 90% CIs fell within the predefined no-effect bounda-
ries of 0.8 to 1.25. AUC0-t values for free platinum were
approximately 30% higher than those for intact oxaliplatin.
A subgroup of 15 patients given an oxaliplatin dose of
130 mg/m2, showed similar trends in pharmacokinetic
parameter ratios and 90% CIs compared to the whole
group, but their Cmax and AUC0-t values for both intact
oxaliplatin and free platinum were higher than for those
given 85 mg/m2.
Motor nerve hyperexcitability
EMGs were performed on Day 2 of treatment cycles one
and two to assess motor nerve excitability. Abnormal
spontaneous high frequency motor unit activity was
detected in 19 of 19 patients (100%) given oxaliplatin with
Ca/Mg and in 16 of 19 patients (84%) given oxaliplatin
with placebo (Figure 3A). An EMG score was calcu-
lated from the severity of motor nerve hyperexcitability
and the number of muscles affected. EMG motor nerve
hyperexcitability score ranged from zero to 16 in different
patient and treatment cycles (Figure 3B). The mean EMG
score was 6.5 (SD, 4.31) with Ca/Mg and 6.2 (SD, 4.34)
with placebo. The mean difference in EMG motor nerve
hyperexcitability scores between placebo and Ca/Mg infu-
sions for each patient was −0.3 (95% CI, -2.2 – 1.6).
Patient-reported acute neurotoxicity symptoms and study
treatment preference
Patient-reported acute neurotoxicity symptoms were simi-
lar in frequency when oxaliplatin was given with placebo
or Ca/Mg infusions (Figure 4A). Cold-induced paresthesia
was reported by 16 of 19 patients (84%) given placebo and
16 of 19 patients (84%) given Ca/Mg infusions. Jaw or
throat tightness was reported by 13 of 19 patients (68%)given placebo and 14 of 19 patients (74%) given Ca/Mg
infusions. Muscle cramps were reported by 8 of 19 pa-
tients (42%) given placebo and 9 of 19 patients (47%) given
Ca/Mg infusions. Few other acute neurotoxicity symptoms
were reported. The preferred study treatment selected by
patients for reducing neurotoxicity symptoms was placebo
in 9 patients (47%), Ca/Mg in 5 patients (26%), and no
preference in 5 patients (26%) (Figure 4B). Significantly
fewer patients preferred Ca/Mg infusions for reducing
their neurotoxicity symptoms than those who preferred
placebo or neither treatment (26% versus 74%; P = 0.01).Discussion
The present study is the first, which we are aware of,
undertaken to evaluate the effects of Ca/Mg infusions
Table 2 Plasma pharmacokinetic parameters of intact oxaliplatin and free platinum in colorectal cancer patients (n=19)
AUC0-t Cmax Cl Vss MRT
(μmol/L*h) (μmol/L) (L/h) (L) (h)
Oxaliplatin dose Study treatment
All (n = 19) Intact oxaliplatin Placebo 15.6 (3.80) 7.62 (1.92) 33.6 (7.70) 57.2 (15.5) 1.68 (0.10)
Ca/Mg 14.8 (3.69) 7.31 (1.91) 35.3 (9.76) 59.3 (14.9) 1.70 (0.13)
Ratio* 0.95 (0.90-1.01) 0.96 (0.90-1.02) 1.05 (0.99-1.12) 1.06 (0.99-1.13) 1.01 (0.99-1.04)
Free platinum Placebo 20.2 (4.12) 9.24 (1.52) 25.9 (6.65) 48.4 (11.3) 1.87 (0.10)
Ca/Mg 19.8 (4.18) 9.52 (1.55) 26.8 (6.03) 50.9 (9.95) 1.90 (0.16)
Ratio* 0.98 (0.93-1.03) 1.03 (0.95-1.12) 1.04 (0.97-1.10) 1.05 (0.99-1.12) 1.02 (0.99-1.05)
130 mg/m2 (n = 15) Intact oxaliplatin Placebo 16.9 (3.32) 8.28 (1.69) 34.5 (7.98) 57.3 (14.3) 1.66 (0.07)
Ca/Mg 15.8 (3.51) 8.01 (1.63) 36.7 (10.2) 60.7 (17.8) 1.66 (0.07)
Ratio* 0.93 (0.86-1.02) 0.97 (0.90-1.04) 1.06 (0.98-1.15) 1.06 (0.98-1.14) 1.00 (0.98-1.02)
Free platinum Placebo 21.8 (3.09) 9.83 (1.06) 26.8 (6.57) 49.7 (11.7) 1.85 (0.05)
Ca/Mg 21.3 (4.45) 10.0 (1.31) 27.8 (6.01) 52.2 (9.82) 1.88 (0.16)
Ratio* 0.98 (0.92-1.04) 1.02 (0.94-1.10) 1.04 (0.97-1.12) 1.05 (0.97-1.14) 1.01 (0.98-1.05)
85 mg/m2 (n = 4) Intact oxaliplatin Placebo 11.4 (1.10) 5.58 (0.74) 30.7 (6.34) 53.8 (12.5) 1.75 (0.18)
Ca/Mg 11.4 (1.03) 5.19 (0.53) 30.7 (5.81) 57.5 (10.3) 1.88 (0.16)
Ratio* 1.00 (0.82-1.22) 0.93 (0.74-1.17) 1.00 (0.87-1.15) 1.07 (0.88-1.31) 1.07 (0.97-1.18)
Free platinum Placebo 15.3 (4.12) 7.32 (1.52) 22.9 (6.89) 43.9 (9.17) 1.92 (0.21)
Ca/Mg 15.0 (2.79) 7.91 (1.35) 23.3 (5.17) 46.4 (10.4) 1.99 (0.17)
Ratio* 0.98 (0.83-1.16) 1.08 (0.73-1.60) 1.02 (0.86-1.21) 1.06 (0.97-1.15) 1.03 (0.91-1.17)
Data values are the geometric mean (standard deviation). Ratio of the geometric mean values for Ca/Mg versus placebo were all close to unity and their 90% CIs
all fell within predefined non-effect boundaries (0.8 to 1.25).
*Ratio of geometric mean (90% CI): with Ca/Mg / with placebo.
Abbreviations: AUC0-t, area under the curve from time 0 (before oxaliplatin dose) to the last concentration (5 hours from the start of the infusion); Cmax, maximum
concentration; Cl, clearance; Vss, volume of distribution at steady state; MRT, mean residence time.
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nerve hyperexcitability. We showed that Ca/Mg infusions
do not alter the pharmacokinetics of either intact oxalipla-
tin or free platinum, and our evidence also indicates that
these infusions may provide no benefit in reducing acuteFigure 3 Oxaliplatin-induced motor nerve hyperexcitability. (A) Repre
unit action potentials detected on electromyography (EMG) on day 2 after
hyperexcitability score by study treatment on day 2 after treatment cycles one
infusions. Individual scores for each patient are joined by the lines. EMG scoreoxaliplatin-induced neurotoxicity. The prospective, ran-
domised, double-blind, placebo-controlled design of our
study, together with the use of objective and patient-
reported endpoints of acute neurotoxicity, eliminates
potential sources of bias and provides reliable results.sentative example of abnormal spontaneous high frequency motor
oxaliplatin treatment (severity grade 4). (B) EMG motor nerve
and two given with placebo (blue circle) or Ca/Mg (gold diamond)































































P (Ca/Mg vs placebo or no preference) = 0.0096
Figure 4 Acute neurotoxicity. (A) Patient reported acute neurotoxicity symptoms; and (B) study treatment preferences. The frequency of acute
neurotoxicity symptoms was similar when oxaliplatin was given with Ca/Mg or placebo infusions. Fewer patients preferred Ca/Mg infusions for
reducing their neurotoxicity symptoms compared to the number who preferred placebo or had no preference.
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between Ca/Mg and oxaliplatin in our study. The plasma
concentration versus time profiles and pharmacokinetic
parameters of intact oxaliplatin and free platinum were
similar when oxaliplatin was given with Ca/Mg or placebo
infusions. Ratios of their pharmacokinetic parameters
were close to unity and their respective 90% CIs fell within
predefined no-effect boundaries of 0.8 and 1.25. We found
intact oxaliplatin to be the major platinum species freely
circulating in the plasma after oxaliplatin treatment,
accounting for approximately 75% and 80% of the free
platinum AUC0-t and Cmax, respectively, as previously
reported [17,21]. The only other study that we are aware of
that attempted to compare the plasma pharmacokinetics
of platinum in patients given oxaliplatin with or without
Ca/Mg infusions was reported by Ishibashi et al. [22].
However, the plasma platinum concentration values reported
in their study were much lower than expected and over 2000-
times lower than those from our study. We suspect that loss
of platinum analyte due to the instability of oxaliplatin and its
reactivity with blood components during the delayed process-
ing of blood samples may have contributed to invalid plasma
platinum concentration measurements in their study,
although it is not possible to be certain about this.
Most patients in our study demonstrated abnormal
spontaneous high-frequency motor unit action potentials
on EMGs undertaken about 24 hours after oxaliplatin, as
previously reported by our group and others [10-12], but
the frequency and severity of these EMG abnormalities
did not reduce with the use of Ca/Mg infusions. Coin-
ciding with this, similar proportion of patients reported
acute neurotoxicity symptoms associated with oxaliplatin
between the two treatment cycles given with or withoutCa/Mg infusions, and fewer patients preferred Ca/Mg infu-
sions than those preferring placebo or neither study treat-
ment. No differences were apparent in EMG scores and
patient reported neurotoxicity symptoms between those
who received 130 mg/m2 and 85 mg/m2 of oxaliplatin, but
this analysis was limited by small sample sizes of these sub-
groups. Although our study suggests that Ca/Mg infusions
may have no effect on oxaliplatin neurotoxicity, it showed
that repeated EMG assessment of motor hyperexcitability
was feasible in patients receiving oxaliplatin chemotherapy.
All patients complied with these procedures without loss
of data in a total of 38 EMGs, thereby proving objective
measurements, which complimented patient-reported end-
points of neurotoxicity. The mechanism of oxaliplatin-
induced motor nerve hyperexcitability remains unclear
but its neurophysiological features are reminiscent of
neuromyotonia [12], and may reflect an acute state of ge-
neralised peripheral nerve hyperexcitability. If motor and
sensory neuropathies are related in this way, future inter-
ventions identified to reduce EMG detectable motor nerve
hyperexcitability may also have potential for preventing
oxaliplatin-induced sensory neurotoxicity.
Our findings disagree with some previous reports
regarding the clinical use of Ca/Mg infusions with oxa-
liplatin. A retrospective analysis by Gamelin et al. was
the first to suggest that Ca/Mg infusions may reduce the
neurotoxicity of oxaliplatin [13]. Then several prospective
randomised trials [14,22-24] attempted to evaluate the
neuroprotective effects of Ca/Mg infusions, but all except
one trial [18] was prematurely terminated when concerns
were raised about lowered tumour responses with Ca/Mg
infusions. The retrospective design and early closures of
subsequent trials may have introduced bias. Evaluation of
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sible in our cross-over study. However, the important ques-
tion about the efficacy of Ca/Mg infusions in preventing
chronic oxaliplatin neurotoxicity was addressed by
Loprinzi et al. in their large prospective randomised
placebo-controlled, double blind trial [25]. They found
that Ca/Mg infusions do not reduce cumulative neur-
opathy of oxaliplatin as measured by the sensory scale
of the EORTC QLQ-CIPN20 tool. Their findings are
complimentary to ours, as both studies, despite their
differing methodologies, demonstrated that Ca/Mg in-
fusions are not effective in reducing oxaliplatin-induced
neuropathy.
Potential limitations of this study include its modest
sample size, single centre design and potential for carryover
effects. The statistical power of this study was considered a
priori when sample size calculations were undertaken using
the pharmacokinetics of oxaliplatin as a primary endpoint.
Subsequently, actual sample sizes and standard deviations
of secondary neurotoxicity endpoints were also used for
post-hoc power analyses. These analyses showed that
with use of a crossover study design, a sample size of
19 or more evaluable patients has adequate statistical
power (≥0.8) to detect fairly large but clinically meaningful
changes in oxaliplatin pharmacokinetics (≥25%), EMG
motor nerve hyperexcitability score (≥40%) and in the
frequency of cold-induced paresthesia (≥38%), with statis-
tical significance (≤0.05). No carry-over effects were evident
between cycles one and two in the pharmacokinetics of
intact oxaliplatin and free platinum or endpoints of
neurotoxicity. Thus, the lack of change found in these
endpoints with Ca/Mg infusions in the current study might
be regarded as true negative findings. This highly efficient
and feasible crossover design maybe applied for future
initial clinical evaluation of other potentially promising
approaches to preventing oxaliplatin neurotoxicity.
Conclusions
Ca/Mg infusions do not alter the clinical pharmacokinetics
of oxaliplatin and do not seem to reduce its acute
neurotoxicity.
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